QGEN

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 9:30 a.m. ET Vice President, Head of Investor Relations - Daniel Wendorff Chief Executive Officer - Thierry Bernard Chief Financial Officer - Roland Sackers Investor Relations - Domenica Martorana Operator: Ladies and gentlemen, thank you for standing by. I am Shelly, your global meet operator. Welcome, and thank you for joining Qiagen's Q2 2026 Earnings Conference Call webcast. [Operator Instructions] Please be advised that the call is being recorded at Qiagen's request and will be made available on the Internet website. [Operator Instructions] At this time, I would like to introduce your host, Daniel Wendorff, Vice President, Head of Investor Relations at Qiagen. Please go ahead. Daniel Wendorff: Thank you, operator, and welcome to our call for the second quarter of 2026. We appreciate your time and interest in Qiagen. Joining the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team. As always, today's call is being webcast live and will be archived in the Investor Relations section of our website at www.qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements. Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20-F and other filings with the U.S. Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with U.S. generally accepted accounting principles or GAAP, that provide additional insights into our performance. Reconciliations to the most directly comparable GAAP figures are in the release and presentation. All references to earnings per share refer to adjusted diluted EPS. With that, let me hand over the call to you -- let me hand over the call to you, Thierry. Thierry Bernard: Thank you, Daniel. Hello, and good morning, good afternoon or good evening, depending on where you are in the world, and thank you for joining us. Let me start by thanking again our teams across Qiagen for their continued dedication and disciplined execution. Their focus enabled us to deliver results above our outlook while continuing to invest in our portfolio and focus on profitable growth. Let me now walk you through our key messages for today. First, we exceeded our outlook for both sales and adjusted EPS. Net sales were $535 million and unchanged on both a reported basis and at CER. This was ahead of our outlook for an approximately 2% decline CER. Adjusted diluted EPS was $0.62 on both a reported basis and at CER again, above our outlook of at least $0.60 at CER. Those results demonstrate the resilience of our business and provide further confidence in our outlook for the year. Second key message, our growth pillars delivered 5% growth at CER, profitably above market growth. Sample Technologies led the quarter, reflecting continued demand for our sample preparation solutions. QIAcuity delivered another solid quarter, driven by healthy consumables demand. QDI, our bioinformatics business also performed well, led by our clinical application. QuantiFERON returned to growth as solid demand across many testing groups more than offset the significant decline in U.S. immigration testing demand. This U.S. immigration testing demand decrease is what we highlighted at the end of our Q1 2026. QIAstat Diagnostic was impacted by a challenging prior year comparison in respiratory testing, partially offset by continued strong growth in our gastrointestinal and meningitis/encephalitis panels with the gastrointestinal panel performing particularly well. Third key message, we maintain a very high level of profitability. This reflects our ability to improve efficiency while continuing to invest for future growth. Fourth, we continue to generate strong cash flow, providing the financial flexibility to invest in the business while returning capital to shareholders. This financial strength enabled us to increase our annual dividend by 40% in 2026. And this brings me to my final key message for today, our outlook for 2026. We are reaffirming our full year outlook and remain confident in stronger growth during the second half of the year. The continued performance of our growth pillars and the progress we are making across our portfolio reinforce our confidence in delivering the outlook we have set for the year. With that, I'll turn over to Roland for more details on the financials. Roland Sackers: Thank you, Thierry, and hello, everyone. As Thierry highlighted, we delivered a better-than-expected second quarter, exceeding our outlook for both sales and adjusted diluted EPS while maintaining a high level of profitability. Let me start with our sales performance across the 4 product groups. Sample Technologies rose 9% CER, driven by automated consumables and higher instrument sales compared to the year ago period. Diagnostic solutions declined 2% at CER. QuantiFERON returned to growth at 1% CER as solid demand across most testing groups more than offset reduced immigration testing demand, primarily in the U.S. and Middle East. QIAstat-Dx sales declined 7% at constant exchange rates despite growth in GI and meningitis panels. However, this was more than offset by lower respiratory panel sales against a challenging prior year comparison previously communicated. In PCR and nucleic acid amplification, sales declined 8% at CER. Our digital PCR system, QIAcuity, delivered double-digit growth at CER, driven by strong consumables demand. This is more than offset by weaker OEM demand. [Technical Difficulty] Operator: [Operator Instructions] You may continue. Roland Sackers: Okay. Sorry for that. It looks like we had some technical difficulties, but I do think we are now back on a call. So let me continue. In PCR and nucleic acid amplifications, sales declined 8% at CER. Our digital PCR system, QIAcuity, delivered double-digit growth at CER, driven by strong consumables demand. This was more than offset by weaker OEM demand. In the genomics and NGS product group, sales rose 2% CER. Qiagen Digital Insights delivered solid single-digit growth, while consumables for universal NGS panels used on third-party sequencers grew more than 20% CER. Lower sales of other genomics products moderated the overall growth rate. Regional performance was mixed during the quarter. Sales in the Americas rose 1% CER, led by 2% growth in North America, while sales declined in Brazil and Mexico. In the EMEA region, sales declined 2% CER. While Spain, Belgium and Poland were up in the quarter, Germany, France and Italy were down. In the Asia Pacific region, sales declined 2% CER. Excluding China, the region grew at a low single-digit rate at constant exchange rates, supported by high teens growth in Japan, while China was down in the low teens. Sequentially, sales in China improved at a double-digit percentage rate. Moving down the income statement. Profitability remained at a high level. Adjusted operating income declined 2% and reached USD 157 million. The adjusted operating income margin was 29.4% compared with 29.9% in the second quarter of '25. Disciplined cost management and efficiency gains helped offset gross margin headwinds. The adjusted gross margin was 66.2% in the quarter compared with 66.7% in the prior year period due to changes in product mix. Operating expenses remained broadly stable as a percentage of sales. Sequentially, the adjusted operating income margin increased by 200 basis points from 27.4% in the first quarter of '26 with higher operating leverage contributing to the improvement. Adjusted diluted EPS was $0.62 at constant exchange rates, exceeding the outlook of at least $0.60 at CER. The adjusted tax rate was 18% in the quarter, in line with our target of 17% to 18%. The high level of profitability also translated into solid cash generation. Operating cash flow was $301 million for the first 6 months of '26, unchanged from the same period of '25. This was achieved despite approximately $20 million of cash payments for efficiency and restructuring programs and a planned increase in inventory. Cash generation was supported by disciplined working capital management and a higher level of profitability. Improved receivables collection and other working capital movements helped offset the inventory build. Days sales outstanding improved to approximately 55 days from approximately 57 days at the end of '25. Days inventory outstanding increased to 153 days from 149 days at the end of '25, reflecting inventory build in preparation for new product launches. Our high level of profitability and cash generation continues to support a strong balance sheet. This gives us the flexibility to invest in innovation, pursue targeted acquisitions and return capital to shareholders. In line with this approach, we completed a $500 million synthetic share repurchase in January and paid our second annual dividend of around $72 million in July. The dividend per share increased by 40% to $0.35 from $0.25 in '25. With that, let me hand back the call to Thierry. Thierry Bernard: Thank you, Roland. And let me now highlight some of the recent progress of our teams in our portfolio. Let's start with Sample Technologies. We continue to make good progress with our automation strategy as more laboratories transition from manual to automated sample preparation. With the commercial launch of QIAsymphony Connect, our new IVD compliant automation system, we reached another important milestone in expanding our automation portfolio. We have started also placing QIAsprint Connect and are pleased with the number of placements, the high level of customer acceptance and the very positive initial feedback, especially from pharma company. QIAmini, our third launch for this year, remains on track for launch this fall with beta field testing beginning in North America in the coming weeks. We are also making very good progress in single cell analysis with Parse. We recently launched the next generation of immune profiling solutions, further expanding our single cell offering. Parse was also selected for a NASA supported research program aboard the International Space Station, supporting research into new treatments for cartilage injuries. Together, those developments show how we are broadening our portfolio while enabling new areas of research in latent tuberculosis testing. As latent tuberculosis screening continues to expand, laboratories are looking for more efficient ways to manage growing testing volumes. Together with DiaSorin and our new automation partner, Inpeco, we plan to launch the first fully automated Sample to Insight workflow in the second half of 2027. This combines sample handling, incubation and detection into one purpose-built automated workflow for QuantiFERON testing. We are also developing an AI-enabled tool to help assess the risk of progression to active TB, providing clinicians with additional insights beyond the detection of latent TB infections. This is how we continue to innovate around QuantiFERON, creating additional value for laboratories and clinicians. On QIAstat, we continue to expand the menu into new testing areas. Bloodstream infections require rapid treatment decisions. With the launch of our 2 new BCID panels, QIAstat now expands into bloodstream infection testing in Europe, providing laboratories with broad coverage across relevant pathogens and antimicrobial resistance markers. Together, those 2 panels detect 33 pathogens and 28 antimicrobial resistance markers in about 1 hour time to result. The next step is to bring those panels to the U.S., and we are confident to get our FDA approval by the end of the year. We are also seeing the value of menu expansion for QIAstat in the field. An example is that during the ongoing cyclospora outbreak in the U.S., our large gastrointestinal panel is helping laboratories respond to increasing testing demand. Turning to digital PCR and QIAcuity now. We continue to advance digital PCR across research, biopharma and clinical application. As more customers are moving from qPCR to digital PCR, they are looking for workflows that are scalable, automated and easy to standardize. This is why we continue to expand the QIAcuity portfolio. This year, in the second half of the year, we are launching new gene expression assays together with a high multiplex kit for the analysis of up to 12 RNA targets in a single reaction. We are also expanding our cell and gene therapy offering with new software and broader workflow automation through our collaboration with Hamilton. We recently demonstrated again the flexibility of QIAcuity during the recent Ebola outbreak, where we rapidly introduced custom digital PCR assays to support infectious disease research and surveillance. Finally, let me touch on Qiagen digital insights development. AI is becoming increasingly important in biomedical research as researchers work with growing amounts of data, but AI is only as valuable as the scientific knowledge behind it. This is where QDI, Qiagen Digital Insights comes in. We combined more than 25 years of curated biomedical knowledge with AI to turn complex biological data into meaningful insights. We, for example, recently announced a new collaboration with NVIDIA. Together, we are combining our curated biomedical knowledge with accelerated computing and graph-based AI. This will help researchers all over the world accelerating drug discovery. With that, let me hand it back to Roland with the details of our outlook for the second half of the year. Roland Sackers: Thank you, Thierry. Let me now provide an update on our outlook for '26 and the third quarter. For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER. We also continue to expect adjusted diluted EPS of at least $2.43 at CER. For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER. I would like to give you some additional perspectives on the expected performance in the second half of the year. We expect CER sales growth to improve from minus 1% in the first half to about 3% to 4% in the second half. This represents a sequential improvement of approximately 4 to 5 percentage points. There are 3 main drivers behind this development. First, the end of the year-on-year headwinds from the discontinued NeuMoDx and DIALUNOX portfolio is expected to contribute approximately 2 percentage points to the improvement in the second half. Second, we expect approximately another 2 percentage points from increasing contributions from new Sample tech systems and other recent and planned product launches. This include QIAsymphony Connect and QIAsprint Connect in Sample Technologies. The rollout of our new BCID panels and continued momentum in companion diagnostics for QIAstat-Dx and additional offerings for QIAcuity. As mentioned earlier, QuantiFERON delivered a stronger second quarter. We continue to believe that we are tracking towards our $500 million target for '26 with easier comparisons expected to support performance in the fourth quarter. Third, we expect approximately 0.5 percentage point from the combined benefits of Parse, which is performing ahead of our original '26 sales target of about USD 40 million and modestly improving trends in the U.S. life science environment. Within the second half, growth is expected to be weighted towards the fourth quarter, which benefits from the incremental contributions from the previously mentioned product launches and an easier prior year comparison following the disruption caused by the U.S. government shutdown in the fourth quarter of '25. The expected allocation towards the second half is also consistent with our historical sales phasing. Approximately 47% of our full year sales are generated in the first half and approximately 53% in the second half of the year. On the topic of tariff repayments, we foresee for the full year. Net of customer refunds, this could be a benefit of about $0.02 EPS at CER. This is already included in our outlook and any additional benefit would be incremental also to our guidance. Finally, let me briefly address currency trends. For the full year, we currently expect a tailwind of about 1 percentage point on sales and a neutral impact on adjusted diluted EPS. This is unchanged from our previous assumptions. For Q3, currency is expected to have a negative impact of about 1 percentage point on net sales, but be neutral on adjusted diluted EPS. With that, I'll now hand it back to Thierry. Thierry Bernard: Thank you, Roland. And now let me briefly summarize before we move to the Q&A session. First, we delivered a quarter above our outlook for both sales and adjusted EPS. At the same time, we maintained a high level of profitability while continuing to invest in our portfolio. Our growth pillars continue to perform well, delivering above-market growth, led by Sample Tech, QIAcuity and QDI, while QuantiFERON returned to growth. We are making good progress in our product launches, supporting our growth ambition for the second half of the year and beyond. Together, the performance of our growth pillars and the progresses on new launches reinforce our confidence in a stronger second half of 2026. So in closing, we remain focused on achieving the outlook we have set for this year and delivering solid profitable growth. With that, I would now like to hand back to the operator for the Q&A session. Thanks a lot once again for your attention. Operator: [Operator Instructions] We will now take the first question comes from your line of Casey Woodring with JPMorgan. Casey Woodring: Maybe just walk through the updated guide for us. I think the back half, you took down from 4% to 3% to 4%. Just maybe walk through kind of what's changed? And then any sort of seasonality that you're assuming from 3Q to 4Q, the step-up that you talked about a little bit Roland in 4Q. Maybe just walk us through the drivers there. Thierry Bernard: Thanks, Casey. I can take the first half of your question and in Roland's comments, we described also the weight of H2 and the traditional seasonality beyond Q4. But -- so first of all, we believe in that acceleration for the reasons that we highlighted. And by the way, we also highlighted the same reason in our Q1 release. You have obviously some positive impact coming from the stop of headwinds coming from the discontinuation last year of NeuMoDx and DIALUNOX. And we expected -- we expect also a significant input from our new launches, especially in Sample tech, but also the new panel that we described today for QIAstat. But at the same time, we want to remain cautious. There is no doubt in our view, Casey, that, for example, funding, especially in the U.S., is improving sequentially. We see indeed an improved funding, especially for research and academia in Q2 compared to Q1. At the same time, we need to highlight that if you consider, for example, the funding coming from NIH in the U.S., it is still below in H1 of 2026 compared to H1 2025. So we see improvement, but we remain also cautious because, as you know, the lack of funding sometimes reflects on capital sales and abilities from labs to invest into new instruments. At the same time, we will benefit definitely from an easier comp from Q4 '25 compared to Q4 '26. Remember that last year, we started the year quite strong in Q1 '25 at 7% growth. We finished the year in Q4 '25 at 1% growth. This is why we have an easier comp. Roland, do you want to give more details on the weight of the different quarters? Roland Sackers: Yes. And probably a couple of different perspectives. First of all, just on some of the products, right? What we just described, Casey is, again, you heard that sample prep is doing quite well, improving quarter-over-quarter. We had now in the first half, 9% growth rate. Again, that will move double digit in the second half of the year, right? QIAstat, we just talked about that for the first half, there was clearly a significant headwind coming from the respiratory business last year. We do believe that business also, again, will turn probably high single, more likely low double-digit growth rate as well in the second half of the year. QIAcuity is probably even accelerating while it's already high double digit in Q1 -- sorry, in H1. So I think there's a lot of things where we, I would say, also have reasonable visibility in a given market environment. So I would say there's things like that. But one thing to you mentioned it before, that is one thing this product launches, right? It takes some time that they gain traction, sample prep, you see it. But of course, every quarter, having instruments on the market, customers getting used to that is being helpful. There is, I think, the natural reason that the fourth quarter will be a stronger one. And have in mind also QIAmini is going to hit within the third quarter, the market. So there's clearly also contribution coming in the first quarter as well. Operator: We'll now take your next question coming from the line of Jack Meehan with Oberon Research. Jack Meehan: For Thierry. So you've announced the strategic review and still have the CEO search going on. I was wondering how should we view the status of the strategic review when a new CEO is named? Does that mean the review stopped? Or could that continue as a separate topic? Any thoughts would be great. Thierry Bernard: Yes. So I think you need to consider that those are 2 complementary but also independent processes. The CEO search, obviously, is one of the highest duty of the Board. We are progressing. We confirm that the transition will happen in H2 of 2026. But at the same time, we have always outlined that our company is always open to consider options to increase shareholder value and stakeholder value. And the Board and management are also fully aware of their fiduciary responsibilities when such discussions might happen. And so it's a constant process at Qiagen where we are constantly looking at the best way to improve value for our shareholders. So I think this is why I continue to say that those processes are natural, long-lasting processes. And the transition with the new CEO should not be viewed as an obstacle to constant improvement of shareholders' value, obviously not. So the 2 processes are going together. Operator: Your next question comes from the line of Tycho Peterson with Jefferies. Tycho Peterson: I want to start with QuantiFERON. You came ahead this quarter, but then you did soften the language on the full year target to "working towards $500 million." Are you baking in incremental headwinds from competition here in the back half of the year? I guess what's changing in the guide on QuantiFERON? And then a follow-up -- just a follow-up on Jack's question. On the strategic review, what's really on the table here? Is this portfolio changes? Is it restructuring? Is it a different mix of capital allocation? I mean you've done a lot. You've gotten rid of NeuMoDx, you're paying a dividend. You have good margins. So I'm just curious how you think about the option set as you do the strategic review. Thierry Bernard: Let me start with the second part of your question, Tycho, and then I will move to QuantiFERON. We are having constant broad strategic reviews. First of all, as you know, we have always said that this company should focus, and we focus where we can gain the most market shares and when we can establish leadership position. This is why we are constantly reviewing the profitability and the return on investment of our different developments in R&D. So it does include the constant assessment, obviously, of our different pillars of growth. Second, it involves also, as I said before, to be always open for discussion as long as we see that it can create value on the long term for our shareholders, for our stakeholders and also when we see a feasibility to a potential basically alliance for another -- with another company. So it's basically a very thorough analysis on everywhere we can make progresses to create more shareholder value. On QuantiFERON itself, I believe we took the right decision at the end of Q1 when we saw the real decrease of migrant testing to take out $35 million of revenues. We said at the end of Q1 that we don't believe that this situation will change drastically in the coming months, the second half of 2026 or even beyond that. That was the right decision to be taken. At the same time, Tycho, we continue to very much make progress in other applications and the development of market shares. First, we continue to convert TST customers to blood test with our latent TB testing. Second, we continue to enter into new applications. We told you 2 years ago, for example, that diabetes was becoming an interesting testing field for latent TB. And if you remember, we said in 2025 that we believe that patients ongoing dialysis were also a significant application potential for latent TB testing. We are starting to implement that. For example, with significant testing labs in the U.S. with the group DaVita, for example. As regard to competition, the fact that new competitors are coming to the market is showing that Qiagen was right many years ago to decide to invest into latent TB testing because I remind you, there is a significant need worldwide for this kind of testing. We showed clearly in our IR session last year that 2 billion people in the world are impacted by latent TB. So the fact that new competitors are entering the market can be seen also positively because it will increase or continue to increase awareness for this kind of testing. And therefore, for me, it's probably going to increase the total available market for latent TB testing worldwide. For H2, now more precisely to your questions. The first thing, first of all, to highlight is, as we highlighted with Roland, Q2 returns to positive growth. We also highlighted in our press release that in Q3, we are going to be slightly impacted by a very strong comp of Q3 2025, especially in the U.S. But overall, we believe that H2 will return to growth, and then we can achieve our target to keep $500 million revenues for QuantiFERON overall. Growth will strengthen as we move into 2027 with our 2 new major development, the partnership with Inpeco and the AI scored results that we are going to launch towards the end of the year next year. Competition has always existed Tycho. Our main competitor is the traditional skin test. We had an existing competition for many years with Revvity, and we have seen the market new entrants. At the moment, we do not see an impact on our market shares. We are prepared to compete commercially and product-wise against any new entrants. But I repeat, the main competitor remain the TST and our main objective remains to continue to convert more TST customers to blood testing. Operator: Your next question comes from the line of Michael Ryskin with Bank of America. Michael Ryskin: First, I want to ask real quick on capital deployment. You had a share authorization at the AGM, but yet it doesn't look like you bought back any shares in the second quarter. Just curious why. Is this have something to do with the strategic review where you kind of want to get that finalized before you deploy capital? Or is there some reason you kind of held back? And I'll throw in a second one, if I can, at the same time. On the Sample Tech business, that continues to do really well, both organic and Parse. You kind of talked about some of the upside to Parse. And obviously, you've got a lot of the automation coming in the new products that you've talked about. Just want to maybe get a sense of your thoughts on that, how that plays out in the second half as you got a little bit tougher comps and beyond, both on the organic and new launches and also on what the upside from Parse could be. Thierry Bernard: So thanks, Michael. And I will take the first part, and I will ask Roland to chime in on the capital deployment strategy. As you noticed, you're right, Michael, it's going very well, but it's a proof that our automation strategy that we started back in 2021 is paying off. I remind you, we started to upgrade some of our existing instruments. QIAcube became QIAcube Connect, EZ1 became EZ2. And this year, we have those 3 new launches. So organically, this is the proof that this strategy is paying off. We continue to see good growth in automated sample tech, and we are absolutely convinced that more customers will move from manual sample tech to automation. So we are having the good set of answers. This is strengthened by the acquisition of Parse because it allows our sample tech portfolio to move into single cells, and we invested and acquired Parse for 2 main reasons. First of all, because the solution of Parse is very highly differentiated compared to existing competition. First, as you know, it's an instrument-free solution. So the ease of use is uncomparable. But at the same time, to address the large volume needs, we can offer also solution with what we call our GigaLab with Parse. And we see that activity also growing very well. The second main differentiation is the number of sales that we can cover with the Parse solutions, which is also uncomparable. This is, for example, behind the fact that we have been chosen by NASA as we highlighted during this call. We told you last year and at the beginning of this year, that the contribution of Parse into our revenues for '26 should be around $40 million. With the development of Q1 and Q2, we believe that we have this number into control, and we can probably exceed it. And now going to Roland for the capital allocation strategy for the coming months. Roland Sackers: Mike, there's always a lot of reasons when to do and when not to do a share buyback at the end of the day. But one thing you have to have in mind, after an AGM, typically debt holders have an opposition period and that in Europe takes somewhere between 2 and 3 months. It's more technical. Typically, there's never any feedback, but you have to wait for that. Operator: Your next question will come from the line of Odysseas Manesiotis with BNP Paribas. Odysseas Manesiotis: I've got 2. Firstly, on the organic growth acceleration implied by your Q3 guide, specifically, I mean, on the midpoint organically, I'm getting around 50 bps acceleration. Wouldn't it be fair to assume improving growth in Sample tech, QIAstat and PCR and nucleic acids given your instrument launches, easing comps and improving funding releases here. Could you help us piece out the divisional growth here relative to Q2 and Q3? And secondly, could you -- I mean, looking at QIAstat, Q2 growth underperformed most of your peers here. And I understand you're relatively more reliant on respiratory, given you're still early on with the GI launches and meningitis, but you held up relatively better in Q4 and Q1. Could you give us some additional color on the Q2 weakness, please? And have you started seeing more U.S. wins since the Rise launch? Thierry Bernard: So different questions. I will start with QIAstat and then move to Q3 and versus Q4. QIAstat, I wouldn't say Odysseas, that we are more exposed to respiratory panels than our competitors. Respiratory panels in syndromic testing account for roughly 65% of the total volume of testing. So it is clear that everybody is sensitive to a stronger flu season or a weaker flu season. Q2 is never -- if you look at our trends in testing for QIAstat over the last years, a very strong quarter for respiratory. Why? Because you are coming out of winter, but in the Northern Hemisphere. And at the same time, you are not completely in winter in many other parts of the world. So this explains the weaker numbers on respiratory. It is true that for the last 12 months, us, but also our competitors are seeing weaker flu season. At the same time, and this is the objective of our strategic vision of developing the menu of QIAstat, we are extremely pleased by the very good growth of GI. The relevance also, you have seen the cyclospora example that I gave today. We have meningitis developing very well, especially in Northern Europe, but also starting in the U.S. And we will have for the second half of the year, the BCID panel because as we said today, blood infections are key issues for customers. We now have that blood culture panel CE marked. We expect to have it FDA approved during the fourth quarter of this year. This will help the growth. A second good factor that will help the growth in end of Q3 and Q4 is that there will be a winter again in the Northern Hemisphere. The problem is not that much to know whether it's going to be a strong flu or weak flu. There will be flu. And here, we will be relevant. And here, you will see an acceleration of our respiratory testing. In the U.S., which remains the main market for syndromic testing, as you know, we have taken significant decisions from an organization standpoint, new sales, salespeople on the field, more specialized, new leadership. This is starting to pay off. And indeed, to your point, where we have the largest volumes of customers, we start to see a good uptake of our QIAstat Rise instrument in North America. So that's the context for QIAstat. And this is why we are confident in a double-digit growth for the second half of the year for QIAstat. Now coming back to your point on Q3 versus Q4. I mean in Q3, we will continue. We have no reason to consider that, for example, Sample tech will slow down. We believe that Sample Tech will continue to perform well because, again, in Q3, we will be more uptake -- we will see more uptake of our new launches, and we see the continuous development of parse. Digital PCR will continue to perform well. Overall between Q3 and Q4, you will see a continuing good development of capital sales and consumables, and this will be also strengthened by the launch of our new set of panels around gene expression. At the same time, as we disclosed today, we know that Q3 will be impacted by a very strong comp on QuantiFERON, especially on North America from Q3 of 2025. This is how we see the development of Q3 versus Q4. Obviously, if we can beat our target for Q3, we will do it. But it's, I think, a very mature and realistic analysis to set that guidance for Q3 and also that acceleration for Q4. Roland Sackers: And just one incremental comment to that because I do think while everybody has it somewhere, I just want to put it also play on the table, right? We shouldn't forget that, again, there's $35 million of immigration sales for QuantiFERON, which are as a market, not accessible for us anymore for anybody. And if you just put that in the percentage growth rate, that is more or less already 6% to 7% growth rate. So again, at the end of the day, that is what we have to compensate. And again, last year, as Thierry just mentioned, Q3 was an 11% growth rate for QuantiFERON. So it is a very strong comparable quarter. The rest of the business is actually, as I said, hard to complain sample prep double-digit second half, QIAstat double-digit second half, QIAcuity double digit. Again, I don't think that we can complain too much. And also again, the headwind Q1 next year on QuantiFERON is history. Operator: Your next question will come from the line of Dan Arias with Stifel. Daniel Arias: Thierry, on the fully automated QuantiFERON solution that you're bringing to market. I know none of this product development is easy, so I don't mean to trivialize the effort. But why 1.5 years to get that product to market? What are the major steps or hurdles to getting that to customers maybe ahead of another competitive option getting into the market? Thierry Bernard: Well, because first of all, you need to develop 2 new instruments and adjust them to the specific workflow of QuantiFERON. Those 2 new systems are a dedicated aliquoter and a dedicated incubator. And then you have to make sure that you can connect all those pieces together to build that first fully automation sample in, result out. So to your question, developing and adapting 2 new instruments in, I would say, something like a year, it's quite a performance -- it's quite a performance. And then obviously, we need to test it with customers. It will be an investment on their side, and we will need to make sure that it is perfectly adapted to their workflow. So there will be some customization. We will work, and we have started to work, especially with our key accounts on making sure that, that workflow from a footprint, from a volume is going to be completely adjusted to their needs. What makes me very confident is that we have started introducing this workflow with a fairly deep level of details to our main customers, main key accounts in the U.S., main key accounts in Europe. And the acceptance, the interest, the welcoming of this presentation is even beyond our expectation with many sites indeed asking to be the pilot site for this fully integrated workflow. But you still need to develop those instruments. You still need to make sure that the workflow is seamless. And I believe that a year to 1.5 years is not that long. You need to validate also the workflow. You need to push it to regulatory approval. So second half of '27 is a realistic time line, and I continue to believe that there will be first installation in that time frame. Operator: Next question will come from the line of Dan Brennan with TD Cowen. Daniel Brennan: Maybe I'll just ask 2 and then kind of mute and listen. Maybe on the first one, Thierry, I think you mentioned upfront to, I think, Jack's question on the strategic plan, both internal efficiency gains and also looking at potential strategic acquirers to maximize value. Could you just comment how management and/or the Board think about private equity versus strategic acquirers? Are they the same? Are they different given PE will typically look at deals and be more cost cut driven versus strategic corporates are going to be probably more growth interested? And then, I guess, b, maybe as we look ahead and kind of when we turn the page, I think consensus right now sits at 5% CER for 2027. So a decent rebound in easy comps. Just wondering if you guys can offer any initial thoughts about how you're looking to exit this year and kind of what that sets up for next year? Thierry Bernard: Well, I would say on the first one, first, I will highlight something because I heard twice in that call the end of the process. And this is not the message that I want to leave with you guys. There is not a date end of a process of continuously assessing the best pathways forward for Qiagen. It's a continuous project. Very regularly during the year, management is reviewing and assessing those options with our Board. And we are not going to stop that at a given point. I think it's management's responsibility to constantly present to the Board options for better shareholder value. So that's the first thing. Now on your question, [ P ] versus strategic, first of all, as you know, Dan, I won't comment in too many details. There are pros and cons on both sides. This is not what is our main driver. Our main driver is to decide, is it better for Qiagen with our midterm plan, with our objective of sales, profitability, return to shareholders? Is it better to continue organically and independently? Would that make sense to have a strategic partner? Or would that make sense to have a more financial-driven partner? What of those solutions is driving the main shareholder value? For our shareholders, but also for our stakeholders, the Qiageners, the legacy that we have built for more than 40 years now. Now regarding the consensus, and Roland, feel free to chime in on this. We are not in a midterm call here, Dan. So I will clearly say our ambition as management for the moment is to deliver on Q3, is to deliver on Q4 to deliver the full guidance that we gave at the beginning of this year. and to continue to improve profitability. The market has not become easier around us. And despite this, this company continues to deliver profitable growth. You have seen that in Q2. That's my main target. We have a target set since our Capital Market Day in June 2024. We are still working towards that. That's what I can say at this moment. Operator: The last question comes from the line of Jan Koch with Deutsche Bank. Jan Koch: My first one is on instruments. You reported a low teens decline in Q2 despite mid-singledigit growth in Sample Tech instruments. in which product category specifically have you seen the highest declines? And most life science companies have actually highlighted improving order trends in lab instruments in Q2. So are you seeing similar trends? And secondly, on QIAstat, how is the development of the complicated UTI panel progressing? And yes, when could you launch this test? Based on the high clinical need for this solution, how do you see the financial opportunity? Thierry Bernard: So let's start with stat and the CAUTI, and then I'll go to the instrument trends and capital sales. The reason why we have extremely good expectation on these complicated UTI panels are mainly twofold. First of all, because, Jan, as you highlighted yourself, this is a significant unmet need for clinicians and for labs all over the world. And once again, you need to understand, we are not talking traditional UTI. This is covered by mainly chip solutions. We are talking about complicated UTI, life-threatening UTI. And there, this is where we have a significant unmet need. And this is a good segue to the second reason to be optimistic is that none of our competitors will have this panel. And to date, none of our competitors have announced that they are developing such a panel. The development progresses very well, and we are still confident that this test will be available for Europe, Europe first in the second half of 2027. And when I say that, I mean, obviously CE Mark, and then we will move to the U.S. You need to understand, Jan, that any time you launch such an innovative panel, there is a period of time where you will have to do clinical and medical education. I have no doubt that our prospect will immediately see the value of the panel, but you need basically to help them changing their testing habit. It always takes time. So we will have to invest in medical education. But the potential of that test, given the unmet need that I highlighted at the beginning is significant. And this will be a very good tool, as we said before, to also help mitigating the respiratory panel going high or going low, depending on the strength of the respiratory season. So it's a very good development. It's a very good strategic development. Now on capital sales. We have said and we continue to say and we have said this even starting in '25, we do see indeed a sequential improvement of funding for research and academia. And this obviously helps capital sales. At the same time, we also highlight that despite that sequential improvement in Q2, for example, compared to Q1 of '26, the NIH outlay year-to-date '26 is still lower than '25. So we remain cautious. We see good progresses, but we remain cautious. And as Roland highlighted in his comments, when you launch a new instrument such as QIAsymphony Connect, such as QIAsprint, for example, Jan, you need to spend some time with customers to validate the new instrument to adjust it to their own needs. That takes a bit of time. So this is why we see that performance of Q2 for capital sales at Qiagen, still lower funding and at the same time, progressive uptake of our new launches. This is how you should see that. But those are good investments for the future. You will see a significant level of QIAsprint placement when we will disclose the numbers at the end of '26. This is creating growth for the future. You will see good placement of QIAsymphony Connect. This will create consumables for the coming years. And as Roland highlighted as well, we will launch also the QIAmini. So if you combine those 2 factors, new systems plus sequential improvement of funding, this gives us good reasons to be optimistic. Operator: This is now -- there will be no more -- this is the end of the Q&A session. I will now turn it back to Daniel for any closing remarks. Daniel Wendorff: Thank you. I would like to close this conference call, and thank you for your participation. If you have any questions or comments, please do not hesitate to contact us. Thank you very much. Operator: Ladies and gentlemen, this concludes the conference call. Thank you for joining, and have a pleasant day. Goodbye. Before you buy stock in Qiagen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Qiagen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $403,337!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,334,946!* Now, it’s worth noting Stock Advisor’s total average return is 958% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Qiagen (QGEN) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Interested in Qiagen N.V.? Here are five stocks we like better. Qiagen exceeded its second-quarter outlook, reporting $535 million in sales, flat year over year, and adjusted diluted EPS of $0.62 versus guidance of at least $0.60. Growth pillars including Sample Technologies, QIAcuity digital PCR and QIAGEN Digital Insights increased 5% at constant exchange rates. Performance varied by product: Sample Technologies rose 9%, while QIAstat-Dx declined 7% and PCR and nucleic acid amplification fell 8% due to weaker respiratory testing comparisons and OEM demand. Margins remained strong at 29.4%, supported by cost controls, and first-half operating cash flow totaled $301 million. Qiagen reaffirmed its full-year guidance for 1%–2% constant-currency sales growth and adjusted EPS of at least $2.43, expecting growth to accelerate to roughly 3%–4% in the second half. New automation, diagnostic and QIAcuity launches are expected to support the outlook, while the CEO search and strategic review continue independently. Strategic Buy Lights Up This Biotech Stock: Time to Invest? Qiagen (NYSE:QGEN) reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings per share were $0.62, exceeding guidance of at least $0.60 at constant exchange rates. Chief Executive Officer Thierry Bernard said the company’s growth pillars rose 5% at constant exchange rates during the quarter, led by Sample Technologies, QIAcuity digital PCR and QIAGEN Digital Insights. He said QuantiFERON latent tuberculosis testing returned to growth despite a significant decline in U.S. immigration testing demand, while QIAstat-Dx faced a difficult comparison in respiratory testing. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling Sample Technologies sales increased 9% at constant exchange rates, supported by automated consumables and higher instrument sales compared with the prior-year period. Diagnostic Solutions revenue declined 2% at constant exchange rates. Within that segment, QuantiFERON grew 1%, as demand across most testing groups outweighed lower immigration testing demand in the U.S. and Middle East. QIAstat-Dx sales fell 7% at constant exchange rates. Growth in gastrointestinal and meningitis panels was offset by lower respiratory-panel sales against a strong prior-year comparison. PCR and nucleic acid amplification sales declined 8%, although QIAcuity delivered double-digit growth driven by consumables demand. The growth in QIAcuity was more than offset by weaker OEM demand, according to Chief Financial Officer Roland Sackers. → 4 Oil and Gas ETF Plays as Prices Stay Sky-High Genomics and next-generation sequencing sales rose 2% at constant exchange rates. QIAGEN Digital Insights posted solid single-digit growth, while consumables for universal NGS panels used on third-party sequencers grew more than 20%. Lower sales of other genomics products moderated the segment’s overall growth rate. Americas sales rose 1% at constant exchange rates, including 2% growth in North America. EMEA sales declined 2%, with gains in Spain, Belgium and Poland offset by declines in Germany, France and Italy. Asia-Pacific sales declined 2%, though the region excluding China grew at a low-single-digit rate and Japan posted high-teens growth. China sales declined in the low teens year over year, but improved sequentially at a double-digit percentage rate. Adjusted operating income declined 2% to $157 million, while the adjusted operating margin was 29.4%, compared with 29.9% in the second quarter of 2025. Sackers said disciplined cost management and efficiency measures helped offset product-mix-related pressure on gross margin. The adjusted cost margin was 66.2%, down from 66.7% a year earlier. → No Hangover: Revisiting Microsoft One Week After Earnings The operating margin improved by 200 basis points sequentially from 27.4% in the first quarter. Qiagen’s adjusted tax rate was 18%, within its 17% to 18% target range. Operating cash flow totaled $301 million for the first six months of 2026, unchanged from the same period in 2025. The figure included approximately $20 million in cash payments tied to efficiency and restructuring programs, as well as a planned inventory increase ahead of product launches. Days sales outstanding improved to approximately 55 days from 57 days at the end of 2025, while days inventory outstanding increased to 153 from 149. The company completed a $500 million synthetic share repurchase in January and paid an approximately $72 million annual dividend in July. The dividend rose 40% to $0.35 per share from $0.25 in 2025. Bernard highlighted progress in the company’s automation portfolio, including the commercial launch of QIAsymphony Connect and early placements of QIAsprint Connect. QIAmini remains scheduled for a fall launch, with beta field testing in North America expected to begin in coming weeks. In diagnostics, Qiagen launched two QIAstat-Dx bloodstream infection panels in Europe that collectively detect 33 pathogens and 28 antimicrobial resistance markers in about one hour. Bernard said the company expects FDA approval for the panels by year-end. Qiagen also expects its complicated urinary tract infection panel to be available in Europe during the second half of 2027. The company plans to launch new QIAcuity gene-expression assays and a multiplex kit for up to 12 RNA targets in a single reaction during the second half of 2026. It is also working with DiaSorin and Inpeco on a fully automated QuantiFERON Sample to Insight workflow, targeted for launch in the second half of 2027. Qiagen reaffirmed its full-year outlook for constant-exchange-rate sales growth of about 1% to 2% and adjusted diluted EPS of at least $2.43. For the third quarter, the company forecast sales growth of approximately 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $0.62. Sackers said the company expects sales growth to improve from a 1% decline in the first half to roughly 3% to 4% in the second half. Management cited the end of headwinds from discontinued NeuMoDx and bioinformatics portfolios, contributions from recent product launches, Parse single-cell analysis performance ahead of its approximately $40 million 2026 sales target, and modestly improving U.S. life-science funding conditions. Bernard said Qiagen’s CEO search and strategic review are complementary but independent processes. He reiterated that the CEO transition is expected during the second half of 2026 and said the company will continue evaluating options intended to increase shareholder and stakeholder value. Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins. The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Qiagen Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.33%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $535.04 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $533.54 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Qiagen shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 13%. While Qiagen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Qiagen was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.64 on $552.19 million in revenues for the coming quarter and $2.43 on $2.14 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Opus Genetics, Inc. (IRD), has yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -25%. The consensus EPS estimate for the quarter has been revised 1.5% lower over the last 30 days to the current level. Opus Genetics, Inc.'s revenues are expected to be $3.02 million, up 5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Opus Genetics, Inc. (IRD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed the Q2 performance to the resilience of growth pillars like Sample Technologies and QIAcuity, while noting that within the QuantiFERON business, solid demand across most testing groups offset the significant decline in U.S. immigration testing demand. The Sample Technologies segment (up 9% CER) is benefiting from a multi-year strategic pivot toward automation, transitioning laboratories from manual workflows to systems like QIAsymphony Connect. QuantiFERON returned to growth despite a $35 million revenue headwind from declining migrant testing, driven by successful market conversion from traditional skin tests to blood-based latent TB testing. QIAstat-Dx performance was hindered by a challenging prior-year comparison in respiratory testing, though management highlighted strong uptake in non-respiratory panels like gastrointestinal and meningitis. The company is maintaining high profitability (29.4% adjusted operating margin) through disciplined cost management and efficiency gains that successfully offset gross margin pressures from product mix changes. Strategic positioning in single-cell analysis via the Parse acquisition is exceeding expectations, with management raising the 2026 sales target for that business beyond the initial $40 million. Regional dynamics remain mixed, with double-digit sequential improvement in China offset by continued cautiousness in U.S. life science funding environments. Management expects CER sales growth to accelerate from -1% in the first half to 3-4% in the second half, driven by the cessation of headwinds from discontinued portfolios. The growth framework assumes approximately 2 percentage points of improvement will come from new product launches, including QIAsymphony Connect, QIAsprint Connect, and the upcoming QIAmini launch. Guidance for QuantiFERON remains at $500 million for the full year, assuming easier year-over-year comparisons in the fourth quarter and continued expansion into new clinical applications like diabetes and dialysis. The company anticipates a stronger Q4 relative to Q3, benefiting from the historical sales phasing where 53% of annual sales typically occur in the second half of the year. Growth in the diagnostics segment will be supported by the expected FDA approval of the BCID panel for QIAstat-Dx in the fourth quarter of 2026, alongside an acceleration in respiratory testing and new panel launches. The company increased its annual dividend by 40% to $0.35 per share, reflecting a commitment to returning capital while maintaining a strong balance sheet for M&A. A $500 million synthetic share repurchase was completed in January 2026, though further buybacks in Q2 were paused due to technical debt-holder opposition periods following the AGM. Management confirmed the CEO transition is on track for the second half of 2026, emphasizing that the search and the ongoing strategic review are independent but complementary processes. A $20 million cash impact was recorded in the first half for efficiency and restructuring programs aimed at long-term margin protection. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management clarified that the strategic review is a continuous process of assessing shareholder value and will not stop when a new CEO is named. The Board remains open to all options, including strategic alliances or financial partnerships, provided they enhance long-term stakeholder value. Thierry Bernard stated that new market entrants validate the latent TB testing market and may increase the total available market by raising awareness. The company does not currently see an impact on market share from new competitors and remains focused on converting the 2 billion people impacted by latent TB from skin tests to blood tests. The launch of the Sample-to-Insight workflow with DiaSorin and Inpeco is slated for H2 2027, requiring the development of a dedicated aliquoter and incubator. Management noted that early feedback from key accounts in the U.S. and Europe regarding this integrated workflow has exceeded internal expectations. Management observed a sequential improvement in research funding in Q2 compared to Q1, though NIH outlays remain lower than the previous year. The decline in instrument sales was attributed to this cautious funding environment and the time required for customers to validate newly launched automation systems.

For the quarter ended June 2026, Qiagen (QGEN) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $527.94 million, representing a surprise of +1.35%. The company delivered an EPS surprise of +3.33%, with the consensus EPS estimate being $0.60. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus the four-analyst average estimate of $36.58 million. The reported number represents a year-over-year change of -5.9%. Sales by Product Groups- Diagnostic solutions- QuantiFERON: $131 million versus $127.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change. Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the three-analyst average estimate of $29.5 million. The reported number represents a year-over-year change of 0%. Sales by Product Groups- Other: $15 million versus $14.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change. Sales by Product Groups- PCR / Nucleic acid amplification: $74 million versus $69.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change. Sales by Product Groups- Genomics / NGS: $61 million versus $59.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change. Sales by Product Groups- Diagnostic solutions: $204 million versus the three-analyst average estimate of $202.46 million. The reported number represents a year-over-year change of -1%. Sales by Product Groups- Sample technologies: $182 million compared to the $181.19 million average estimate based on three analysts. The reported number represents a change of +9.6% year over year. View all Key Company Metrics for Qiagen here>>> Shares of Qiagen have returned +9.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Wall Street expects a year-over-year decline in earnings on lower revenues when Cytokinetics (CYTK) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This biopharmaceutical company is expected to post quarterly loss of $1.63 per share in its upcoming report, which represents a year-over-year change of -45.5%. Revenues are expected to be $20.42 million, down 69.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.26% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Cytokinetics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.07%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Cytokinetics will most likely beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Cytokinetics would post a loss of$1.67 per share when it actually produced a loss of -$1.67, delivering no surprise. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Cytokinetics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Qiagen (QGEN), is soon expected to post earnings of $0.6 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -4.8%. This quarter's revenue is expected to be $527.94 million, down 1.1% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Qiagen has been revised 0.8% down to the current level. Nevertheless, the company now has an Earnings ESP of -0.28%, reflecting a lower Most Accurate Estimate. This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Qiagen will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

The market expects Qiagen (QGEN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This diagnostic products maker is expected to post quarterly earnings of $0.60 per share in its upcoming report, which represents a year-over-year change of -4.8%. Revenues are expected to be $527.94 million, down 1.1% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.78% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Qiagen, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.28%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Qiagen will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Qiagen would post earnings of $0.55 per share when it actually produced earnings of $0.54, delivering a surprise of -1.82%. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Qiagen doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Rhythm Pharmaceuticals, Inc. (RYTM), is soon expected to post loss of $0.82 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -9.3%. This quarter's revenue is expected to be $65.87 million, up 35.8% from the year-ago quarter. The consensus EPS estimate for Rhythm Pharmaceuticals has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +1.46%. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Rhythm Pharmaceuticals will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Rhythm Pharmaceuticals, Inc. (RYTM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It has been about a month since the last earnings report for Qiagen (QGEN). Shares have added about 12.1% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. QIAGEN (QGEN) reported first-quarter 2026 adjusted EPS of 54 cents, unchanged at CER. The reported figure declined 2% year over year and missed the Zacks Consensus Estimate by 1.2%. The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, EPS in the first quarter was 33 cents compared with 41 cents in the year-ago period. Net sales in the first quarter were $492 million, up 2% year over year (down 1% at CER). The top line missed the Zacks Consensus Estimate by 0.8%. QIAGEN has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). The Zacks Consensus Estimate for revenues is pegged at $2.18 billion. Adjusted EPS is now expected to be at least $2.43 CER (previously at least $2.50 CER). The Zacks Consensus Estimate for EPS is pegged at $2.45 billion. For second-quarter 2026, net sales are expected to decline approximately 2% year over year at CER. The Zacks Consensus Estimate is currently pegged at $537.9 million. Adjusted EPS is expected to be at least $0.60 CER. The Zacks Consensus Estimate is pegged at 61 cents. It turns out, estimates revision have trended downward during the past month. At this time, Qiagen has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Following the exact same course, the stock has a score of B on the value side, putting it in the second quintile for value investors. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Qiagen has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months. Qiagen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, GSK (GSK), a stock from the same industry, has gained 1.5%. The company reported its results for the quarter ended March 2026 more than a month ago. Glaxo reported revenues of $10.28 billion in the last reported quarter, representing a year-over-year change of +8.6%. EPS of $1.24 for the same period compares with $1.13 a year ago. For the current quarter, Glaxo is expected to post earnings of $1.29 per share, indicating a change of +4.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Glaxo. Also, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research